Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia

Ralph Boccia, Imtiaz A. Malik, Vinay Raja, Stephen Kahanic, Randall Liu, Tom Lillie, Dianne Tomita, Billy Clowney, Peter Silberstein

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

Patients with cancer receiving chemotherapy often have chemotherapy-induced anemia (CIA) and reduced quality of life. Darbepoetin alfa can effectively treat CIA when administered at an extended dosing interval of once every 3 weeks (Q3W). Darbepoetin alfa administered Q3W may allow synchronization of darbepoetin alfa therapy with chemotherapy administered Q3W. This multicenter, open-label, 16-week study evaluated the effectiveness and safety of darbepoetin alfa administered as a fixed dose (300 μg) Q3W in patients with CIA. Eligible patients (≥18 years) were anemic (hemoglobin

Original languageEnglish (US)
Pages (from-to)409-417
Number of pages9
JournalOncologist
Volume11
Issue number4
DOIs
StatePublished - Apr 1 2006

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia'. Together they form a unique fingerprint.

  • Cite this